- Conditions
- High Risk Prostate Carcinoma, Prostate Cancer
- Interventions
- Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C), Magnetic Resonance Imaging (MRI), Non-investigational radical prostatectomy (RP), Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)
- Drug · Procedure
- Lead sponsor
- Ivan de Kouchkovsky, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–155
of 155
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- enzalutamide, abiraterone acetate, prednisone
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Apalutamide, Abiraterone acetate, Docetaxel, Prednisone
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • New York, New York
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- BEZ235, BKM120
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Hackensack, New Jersey
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
- Interventions
- CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
- Drug
- Lead sponsor
- CellCentric Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
- Interventions
- TAVT-45, Zytiga, Prednisone
- Drug
- Lead sponsor
- Tavanta Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Newly Diagnosed Oligometastatic Prostate Cancer
- Interventions
- radical prostatectomy, stereotactic body radiotherapy, Leuprolide, apalutamide, abiraterone
- Procedure · Radiation · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Long Beach, California • West Los Angeles, California • Richmond, Virginia
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Positron Emission Tomography, Lymphadenectomy, Radiation Therapy, Abiraterone Acetate, Prednisone, Computed Tomography, Abiraterone, PSMA PET Scan
- Procedure · Radiation · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2037
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Prostate Cancer, Oligometastatic Disease
- Interventions
- niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
- Drug · Radiation
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- enzalutamide, abiraterone acetate, prednisone, Leuprolide acetate
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 46
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 38 more
- Conditions
- Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Interventions
- XL102, Fulvestrant, Abiraterone, Prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more